Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...
The MarketWatch News Department was not involved in the creation of this content. -- Focused Execution Drives Strong Full-Year 2025 EPS Performance -- Enters 2026 with Clear Strategic Priorities and ...
The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...
Augments Pfizer’s efforts to advance investigational medicines for cardiometabolic diseases Pfizer plans to conduct combination studies of YP05002 with its glucose-dependent insulinotropic polypeptide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results